Add Formweb to your mobile device
Search results for:
tocilizumab
tocilizumab
Brand names: Actemra
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, INTRAVENOUS | 20 mg/mL | Restricted |
Last updated: Dec. 9, 2024
- Black Box Warning: Serious infections risk
- Do Not Tube-LALK
- Restricted: Tocilizumab (Actemra) is formulary, restricted to use in the outpatient setting. Restricted use in the inpatient setting for treatment of patients with specific indications (see comments).
Tocilizumab Executive Summary
Formulary, restricted to use in the outpatient setting. Restricted use in inpatient setting for oncology patients with cytokine release syndrome related to: bi-specific T-cell engaging therapy; Chimeric antigen receptor T-cell therapy (CAR T-cell Therapy); or post allogeneic stem cell transplant.
***Tocilizumab (Actemra) is temporarily approved for use in cytokine storm related to COVID-19. Please reach out to Pharmacy Leadership for acquisition. See COVID-19 Treatment Recommendations for dosing.